Condition: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy · Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy · Wild-Type Transthyretin Cardiac Amyloidosis · Sponsor: Intellia Therapeutics
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
This description comes directly from the study's public registry record.
Trial Manager at Intellia · 1-857-285-6200 · medicalinformation@intelliatx.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Paris, France | Recruiting |
| Clinical Trial Site | Auckland, New Zealand | Recruiting |
| Clinical Trial Site | Umeå, Sweden | Recruiting |
| Clinical Trial Site | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05697861